Goldman Jonathan W, Dvorkin Mikhail, Chen Yuanbin, Kollaborációs szervezet: CASPIAN investigators, Losonczy György, Horváth Zsolt, . . . Pápai Zsuzsanna. (2021). Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial.
Chicago Style (17th ed.) CitationGoldman Jonathan W, et al. Durvalumab, with or Without Tremelimumab, Plus Platinum-etoposide Versus Platinum-etoposide Alone in First-line Treatment of Extensive-stage Small-cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-label, Phase 3 Trial. 2021.
MLA idézésGoldman Jonathan W, et al. Durvalumab, with or Without Tremelimumab, Plus Platinum-etoposide Versus Platinum-etoposide Alone in First-line Treatment of Extensive-stage Small-cell Lung Cancer (CASPIAN): Updated Results from a Randomised, Controlled, Open-label, Phase 3 Trial. 2021.